These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 22514189)
1. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. di Minno MN; Peluso R; Iervolino S; Lupoli R; Russolillo A; Scarpa R; di Minno G Arthritis Care Res (Hoboken); 2013 Jan; 65(1):141-7. PubMed ID: 22514189 [TBL] [Abstract][Full Text] [Related]
2. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. Iervolino S; Di Minno MN; Peluso R; Lofrano M; Russolillo A; Di Minno G; Scarpa R J Rheumatol; 2012 Mar; 39(3):568-73. PubMed ID: 22247361 [TBL] [Abstract][Full Text] [Related]
3. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers. Di Minno MN; Iervolino S; Peluso R; Russolillo A; Lupoli R; Scarpa R; Di Minno G; Tarantino G; J Rheumatol; 2012 May; 39(5):1042-6. PubMed ID: 22422493 [TBL] [Abstract][Full Text] [Related]
4. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Di Minno MN; Peluso R; Iervolino S; Russolillo A; Lupoli R; Scarpa R; Ann Rheum Dis; 2014 Jun; 73(6):1157-62. PubMed ID: 23771989 [TBL] [Abstract][Full Text] [Related]
5. Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis--effect of different treatments. Di Minno MN; Iervolino S; Peluso R; Di Minno A; Ambrosino P; Scarpa R; J Rheumatol; 2014 Apr; 41(4):714-22. PubMed ID: 24532831 [TBL] [Abstract][Full Text] [Related]
6. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Eder L; Thavaneswaran A; Chandran V; Cook RJ; Gladman DD Ann Rheum Dis; 2015 May; 74(5):813-7. PubMed ID: 24431392 [TBL] [Abstract][Full Text] [Related]
7. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. Barra L; Pope JE; Payne M J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267 [TBL] [Abstract][Full Text] [Related]
8. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258 [TBL] [Abstract][Full Text] [Related]
9. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study. Kristensen LE; Englund M; Neovius M; Askling J; Jacobsson LT; Petersson IF Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309 [TBL] [Abstract][Full Text] [Related]
10. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Koldingsnes W; Mowinckel P; Kvien TK Ann Rheum Dis; 2007 Aug; 66(8):1038-42. PubMed ID: 17213251 [TBL] [Abstract][Full Text] [Related]
11. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs. Perrotta FM; Marchesoni A; Lubrano E J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925 [TBL] [Abstract][Full Text] [Related]
12. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816 [TBL] [Abstract][Full Text] [Related]
13. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy. Iannone F; Fanizzi R; Scioscia C; Anelli MG; Lapadula G Scand J Rheumatol; 2013; 42(1):41-4. PubMed ID: 22991950 [TBL] [Abstract][Full Text] [Related]
14. Body weight, gender and response to TNF-α blockers in axial spondyloarthritis. Gremese E; Bernardi S; Bonazza S; Nowik M; Peluso G; Massara A; Tolusso B; Messuti L; Miceli MC; Zoli A; Trotta F; Govoni M; Ferraccioli G Rheumatology (Oxford); 2014 May; 53(5):875-81. PubMed ID: 24407233 [TBL] [Abstract][Full Text] [Related]
15. Malignancies developing in obese patients with psoriasis while on antitumour necrosis factor-α therapies: a case series. Sadlier M; Lally A; Kirby B Br J Dermatol; 2012 Oct; 167(4):937-8. PubMed ID: 22428935 [No Abstract] [Full Text] [Related]
16. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Coates LC; Cawkwell LS; Ng NW; Bennett AN; Bryer DJ; Fraser AD; Emery P; Marzo-Ortega H Ann Rheum Dis; 2008 May; 67(5):717-9. PubMed ID: 18055476 [TBL] [Abstract][Full Text] [Related]
17. Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study. Di Minno MN; Peluso R; Iervolino S; Lupoli R; Russolillo A; Tarantino G; Scarpa R Arthritis Res Ther; 2012 Oct; 14(5):R211. PubMed ID: 23036698 [TBL] [Abstract][Full Text] [Related]
18. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Söderlin MK; Petersson IF; Geborek P Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371 [TBL] [Abstract][Full Text] [Related]